Background: To compare the postoperative continence and clinical outcomes of Retzius-sparing robot-assisted laparoscopic radical prostatectomy (RS-RALP) with non-RS RALP for patients with prostate cancer.
Methods: We searched PUBMED, EMBASE and the Cochrane Central Register from 1999 to 2019 for studies comparing RS-RALP to non-RS RALP for the treatment of prostate cancer. We used RevMan 5.2 to pool the data.
Results: A total of seven studies involving 1620 patients were included in our meta-analysis. No significant difference was found in positive surgical margins (PSM), bilateral nerve-sparing, postoperative hernia, complications, blood loss, or operative time. Postoperative continence was better with RS-RALP compared with non-RS RALP (OR = 1.02, OR: 2.86, 95% CI 1.94-4.20, p < 0.05).
Conclusions: RS-RALP had a better recovery of postoperative continence than non-RS RALP. The perioperative outcomes were comparable for the two methods.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398331 | PMC |
| http://dx.doi.org/10.1186/s12894-020-00685-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The p16 Immunostaining Predicts the Risk of Recurrence in Prostate Cancer.
Asian Pac J Cancer Prev
January 2025
Postgraduate Program in Oncology, Haroldo Juaçaba Hospital, Ceará Cancer Institute (ICC), Brazil.
Objective: This study aimed to investigate the influence of p16 immunohistochemical expression on the biochemical recurrence rate of pT2-pT3 prostate cancer.
Materials And Methods: A total of 488 pT2-pT3 stage prostate adenocarcinomas undergoing radical prostatectomy were included in this study. Following a review of Gleason classification and retrieval of sociodemographic and clinicopathological data, as well as the date of last consultation and biochemical recurrence, immunohistochemistry for p16 was performed.
Three-dimensional (3D) augmented reality during Retzius-sparing robot-assisted radical prostatectomy (RS-RARP): First experience.
Cancer Pathog Ther
January 2025
Department of Urology, ASST Grande Ospedale Metropolitano Niguarda, Milan 20162, Italy.
The Role of Immunohistochemistry for AMACR/p504s and p63 in Distinguishing Prostate Cancer from Benign Prostate Tissue Samples in Botswana.
Res Rep Urol
January 2025
Department of Pathology, Faculty of Medicine, University of Botswana, Gaborone, Botswana.
Introduction: Prostate cancer (CaP) is the most common malignancy and the second leading cause of cancer-related deaths among men in Botswana. Currently, diagnosing CaP relies on examining prostate biopsy samples, which can be challenging due to benign mimics. This study aims to evaluate the potential of Alpha-methyl acyl-CoA racemase (AMACR/p504s) and p63, as diagnostic markers for CaP.
View Article and Find Full Text PDFhUC-MSC preserves erectile function by restoring mitochondrial mass of penile smooth muscle cells in a rat model of cavernous nerve injury via SIRT1/PGC-1a/TFAM signaling.
Biol Res
January 2025
Department of Urology and Andrology, Renji Hospital, Shanghai Institute of Andrology, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.
Background: Cavernous nerve injury-induced erectile dysfunction (CNI-ED) is a common complication following radical prostatectomy and severely affects patients' quality of life. The mitochondrial impairment in corpus cavernosum smooth muscle cells (CCSMCs) may be an important pathological mechanism of CNI-ED. Previous studies have shown that transplantation of human adipose derived stem cells (ADSC) can alleviate CNI-ED in a rat model.
View Article and Find Full Text PDFExternal beam radiation therapy versus radical prostatectomy for high-risk prostate cancer: protocol of the RECOVER study.
BMC Cancer
January 2025
Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands.
Background: This paper describes the rationale and design of the RECOVER study. Currently, there is no consensus regarding the optimal treatment for high-risk, non-metastatic prostate cancer (PCa). The study primarily aims to evaluate and compare the impact of treatment with robot-assisted radical prostatectomy (RP) versus external beam radiation therapy (EBRT) with androgen deprivation therapy (ADT) for men with high-risk, non-metastatic PCa regarding health-related quality of life (HRQoL) and functional outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!